{"page_content": "9      KODIAK 2021 ESG REPORT BACK TO CONTENTS >>cause of irreversible blindness worldwide, but no treatment currently exists \nthat directly addresses the underlying biology of retinal neural cell loss which is \nmultifactorial in nature.\nHow our medicine could help: We aim to fill this significant gap with our triplet \nmedicines, including KSI-601, which combine the benefits of our ABC Platform \nfor long-interval dosing of biologics with a new feature that adds sustained release \nof small molecules, to target three mechanisms of action enabling treatment of \nthese complex diseases. We refer to these as triplet medicines due to this multiple \napproach, which is unique in the field.\nWHAT WE VALUE\nOur values reflect our culture and mission and are designed  \nto drive our progress towards our goals.\nHistorically referred to within the Company as \u201cthe 4 C\u2019s,\u201d our values are: \nCURIOSITY\nCREATIVITYCOMPASSION \n \nCOURAGEKODIAK AT-A-GLANCE \nHeadquarters in Palo Alto, California\nNew state-of-the-art research  \nand development (\u201cR&D\u201d) facility in  \nPalo Alto, California\nGlobal manufacturing partners with \nlocations in Switzerland, United States and \nChina\n~100  employees worldwide \n6 registrational clinical trials ongoing  \nin parallel for KSI-301 in 2021\n3 ABC Platform-based molecules in \nKodiak\u2019s pipeline\n\u2022 KSI-301 \u2014 in phase 3 clinical trials\n\u2022  KSI-501 \u2014 expected to commence  \nclinical trial phase in 2022 \n\u2022 KSI-601 \u2014 preclinical phase \n4 ophthalmic diseases targeted in  \nKSI-301 clinical program\n2,500+  trial participants in KSI-301 \nclinical program in 2021", "metadata": {"source": "NASDAQ_KOD_2021.pdf", "page": 8, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}